Avid Radiopharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Philadelphia PA United States (2005)
Status: Acquired by Eli Lilly (2010)

Organization Overview

First Clinical Trial
2007
NCT01565291
First Marketed Drug
2012
florbetapir (Amyvid)
First NDA Approval
2012
florbetapir (Amyvid)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Avid Radiopharmaceuticals | Avid Radiopharmaceuticals, Inc. | AVID RADIOPHARMS INC